Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABT 
Abbott Laboratories (ABT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: ABT (2-star) is a SELL. SELL since 1 days. Profits (-0.77%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $141.32
1 Year Target Price $141.32
| 12 | Strong Buy |
| 7 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.07% | Avg. Invested days 43 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 229.69B USD | Price to earnings Ratio 17.15 | 1Y Target Price 141.32 |
Price to earnings Ratio 17.15 | 1Y Target Price 141.32 | ||
Volume (30-day avg) 28 | Beta 0.74 | 52 Weeks Range 98.26 - 140.58 | Updated Date 07/13/2025 |
52 Weeks Range 98.26 - 140.58 | Updated Date 07/13/2025 | ||
Dividends yield (FY) 1.74% | Basic EPS (TTM) 7.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-17 | When Before Market | Estimate 1.26 | Actual - |
Profitability
Profit Margin 31.89% | Operating Margin (TTM) 18.09% |
Management Effectiveness
Return on Assets (TTM) 6.38% | Return on Equity (TTM) 30.65% |
Valuation
Trailing PE 17.15 | Forward PE 25.64 | Enterprise Value 236091305823 | Price to Sales(TTM) 5.42 |
Enterprise Value 236091305823 | Price to Sales(TTM) 5.42 | ||
Enterprise Value to Revenue 5.58 | Enterprise Value to EBITDA 21.32 | Shares Outstanding 1739840000 | Shares Floating 1729780210 |
Shares Outstanding 1739840000 | Shares Floating 1729780210 | ||
Percent Insiders 0.54 | Percent Institutions 80.49 |
Upturn AI SWOT
Abbott Laboratories
Company Overview
History and Background
Abbott Laboratories was founded in 1888 by Dr. Wallace Calvin Abbott. Initially a pharmaceutical preparation business, it has evolved into a global healthcare leader through strategic acquisitions and product development.
Core Business Areas
- Diagnostics: Develops and manufactures diagnostic systems and tests for hospitals, labs, blood banks, and point-of-care settings.
- Medical Devices: Offers a range of medical devices, including cardiac devices, electrophysiology, heart failure, vascular, and structural heart devices.
- Nutrition: Provides nutritional products for infants, children, and adults, including Similac and Ensure.
- Established Pharmaceuticals: Focuses on branded generic pharmaceuticals in emerging markets.
Leadership and Structure
Robert B. Ford is the Chairman and CEO. The company operates with a divisional structure aligned with its core business areas.
Top Products and Market Share
Key Offerings
- Market Share: 0.13
- Revenue: 1800000000
- Similac: Infant formula. Market share varies by region; a leading brand globally. Competitors include Nestle's Gerber and Reckitt Benckiser's Enfamil.
- Ensure: Adult nutrition products. Holds a significant market share in the adult nutrition market. Competitors include Nestle's Boost and various generic brands.
- Market Share: 0.25
- Revenue: 5000000000
- FreeStyle Libre: Continuous glucose monitoring system. A leading CGM device with growing market share. Competitors include Dexcom and Medtronic.
- Market Share: 0.43
- Revenue: 4300000000
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by aging populations, technological advancements, and increasing prevalence of chronic diseases.
Positioning
Abbott is a diversified healthcare company with a strong presence in diagnostics, medical devices, nutrition, and pharmaceuticals, providing a stable base in a competitive market.
Total Addressable Market (TAM)
The total addressable market for Abbott's segments is estimated at over $500 billion. Abbott is well-positioned with its diverse portfolio and global reach to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Diversified Product Portfolio
- Strong Brand Recognition
- Global Presence
- Consistent Dividend Payouts
- Innovation in Medical Devices
Weaknesses
- Exposure to Currency Fluctuations
- Reliance on Key Products
- Competition in Established Markets
- Price pressures on generic medications
- Product recalls
Opportunities
- Expansion in Emerging Markets
- Growth in Diagnostic Testing
- Development of New Medical Technologies
- Strategic Acquisitions
- Increased demand for nutritional products
Threats
- Increased Competition
- Regulatory Changes
- Economic Downturns
- Patent expirations
- Healthcare reform policies
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Medtronic (MDT)
- Danaher (DHR)
- Siemens Healthineers (SEMHF)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Abbott's diversified portfolio provides a competitive advantage. However, it faces stiff competition in specific segments from larger and more specialized players.
Major Acquisitions
St. Jude Medical
- Year: 2017
- Acquisition Price (USD millions): 25000
- Strategic Rationale: Expanded Abbott's cardiovascular device portfolio.
Alere
- Year: 2017
- Acquisition Price (USD millions): 5300
- Strategic Rationale: Enhanced Abbott's diagnostics capabilities.
Growth Trajectory and Initiatives
Historical Growth: Abbott has demonstrated steady growth through organic product development and strategic acquisitions.
Future Projections: Analysts project continued revenue growth in the mid-single digits, driven by demand for medical devices and diagnostics. EPS is expected to grow at a faster pace due to margin improvements.
Recent Initiatives: Recent initiatives include the launch of new medical devices, expansion into emerging markets, and investments in R&D.
Summary
Abbott Laboratories is a strong, diversified healthcare company with a long history and global presence. Its diverse product portfolio and consistent dividend payouts make it an attractive investment. However, it faces increasing competition and regulatory challenges and needs to keep an eye on global currency fluctuations and the increasing cost of generic medicine production.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Abbott Laboratories Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 1978-01-13 | Chairman of the Board, President & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114000 | Website https://www.abbott.com |
Full time employees 114000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.